Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... The Centers for Medicare & Medicaid Services reported that healthcare spending in the US reached $4.9 trillion ...
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Novo Nordisk's stock rose about 5% on Friday ... weight loss drugs such as Wegovy are not currently covered by Medicare and other insurance.
Novo Nordisk's stock closed about 5% higher on ... weight loss drugs such as Wegovy are not currently covered by Medicare and other insurance. Don't expect a 20% S&P 500 three-peat this year ...